The global pulmonary arterial hypertension market size accounted for USD 8.06 billion in 2024, grew to USD 8.48 billion in 2025 and is expected to be worth around USD 13.50 billion by 2034, registering a healthy CAGR of 5.30% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pulmonary Arterial Hypertension Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pulmonary Arterial Hypertension Market, by Drug Class, 2024-2034
8.1.1 Endothelin Receptor Antagonists (ERAs)
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. PDE-5 Inhibitors
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Prostacyclin and Prostacyclin Analogs
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. SGC Stimulators
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Pulmonary Arterial Hypertension Market, by Type, 2024-2034
9.1.1. Branded
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Generics
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Pulmonary Arterial Hypertension Market, by Route of Administration, 2024-2034
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Intravenous/ subcutaneous
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Inhalational
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.2. Market Revenue and Forecast, by Type (2021-2034)
11.1.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1. Actelion Pharmaceuticals (now part of Janssen Pharmaceuticals)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Gilead Sciences
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. United Therapeutics Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pfizer
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Arena Pharmaceuticals
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Reata Pharmaceuticals
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Lung Biotechnology
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Acceleron Pharma
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample